Gloria Moussa Gabour, MD
Family Medicine · Melrose, MANPI 1376505222
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 287 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AstraZeneca at 24.4% of the total. Reporting peaked in 2019 at $1,109 and has fallen 73.6% since, to $292 in 2025. Among family medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 287 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$716
- Novo Nordisk$444
- Astellas Pharma US Inc$396
- Boehringer Ingelheim$379
- Lilly USA, LLC$279
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,27997%
- Education$1853%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 56 | $1,331 |
| AbbVie(2 entities) | 42 | $716 |
| Novo Nordisk | 18 | $444 |
| Astellas Pharma US Inc | 14 | $396 |
| Boehringer Ingelheim | 21 | $379 |
| Lilly USA, LLC | 14 | $279 |
| GSK | 15 | $269 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $174 |
| Valeritas, Inc. | 15 | $173 |
| Pfizer | 10 | $167 |
| Amgen | 7 | $161 |
| Merck | 7 | $122 |
| Exact Sciences | 4 | $102 |
| Mylan Specialty L.p. | 5 | $92 |
| Shield Therapeutics Inc | 5 | $80 |
| Lundbeck LLC | 4 | $70 |
| Genentech USA, Inc. | 4 | $70 |
| Sanofi Pasteur Inc. | 4 | $66 |
| Abbott | 3 | $64 |
| Amarin Pharma, Inc. | 3 | $60 |
| Bayer | 3 | $57 |
| Sunovion Pharmaceuticals Inc. | 4 | $40 |
| Zealand Pharma US, Inc. | 2 | $38 |
| Novartis | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Bausch Health US, LLC | 1 | $17 |
| Vivus LLC | 1 | $16 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEVESPI AEROSPHERE$138
- SYMBICORT$138
- FARXIGA$138
- Ozempic$122
- FASENRA$121
How this compares
$5,464 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 23 | $28,600 |
| JardianceEmpagliflozin | 23 | $27,722 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $20,810 |
| TradjentaLinagliptin | 11 | $16,471 |
| MounjaroTirzepatide | 14 | $14,604 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $4,621 |
| Metoprolol Succinate | 133 | $3,257 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $3,088 |
| Rosuvastatin Calcium | 47 | $2,511 |
| Atorvastatin Calcium | 108 | $1,875 |
| Solifenacin Succinate | 15 | $1,759 |
| FenofibrateFenofibrate,micronized | 17 | $1,637 |
| Ezetimibe | 24 | $1,577 |
| Ibandronate Sodium | 31 | $1,508 |
| Omeprazole | 89 | $1,300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $379 | $44,19234 claims |
| PfizerEliquis | $167 | $28,60023 claims |
| GSKTrelegy Ellipta | $269 | $20,81022 claims |
| Lilly USA, LLCMounjaro | $279 | $14,60414 claims |
| AbbVieSynthroid | $716 | $33212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Other family medicine in Melrose
- Larry CulpepperBoston$109K
- Jennifer WeylerWorcester$105K
- Megan McCoyFramingham$75K
- Kristina GraceyWorcester$73K
- Suzanne MitchellBoston$69K
- John GrievesonLowell$24K
- James SalemisRoslindale$24K
- David FarzanLawrence$23K
- Julie JohnstonLawrence$21K
- Sanjeev SharmaFramingham$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.